Optimizing Pharmacotherapy In Chronic GVHD

Chronic graft-versus-host disease can occur in a multitude of organs, often characterized by fibrosis or ...

JUNE 16, 2025

Steroids Still the Mainstay Treatment for cGVHD

Corticosteroids remain an effective tool for treating chronic graft-versus-host disease, although they are ...

DECEMBER 20, 2024

FDA Approves Ryoncil for Steroid-Refractory Acute Graft-Versus-Host Disease in Pediatric Patients

The FDA approved Ryoncil, an allogeneic bone marrow–derived mesenchymal stromal cell therapy, for ...

DECEMBER 19, 2024

Long-Term Management of Solid-Organ and Hematopoietic Cell Transplant Recipients

The long-term success of solid-organ transplant recipients greatly hinges on effective maintenance ...

DECEMBER 15, 2024

FDA Approves Niktimvo for Chronic Graft-Versus-Host Disease

The FDA has approved Niktimvo for the treatment of chronic graft-versus-host disease after failure of at least two ...

AUGUST 15, 2024

FDA Approves Jakafi to Treat Acute GVHD

The FDA granted a new indication for Jakafi to treat steroid-refractory acute graft-versus-host disease in adults ...

MAY 28, 2019

FDA Approves Imbruvica to Treat Adults With Chronic GVHD

Imbruvica becomes the first and only therapy specifically approved for adults with cGVHD, a serious and ...

AUGUST 7, 2017